Evidence map›Paper›PMID 23380890›Full record

Trial reportJAMA pediatrics2013

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.

Aaron S Kelly, Kyle D Rudser, Brandon M Nathan, Claudia K Fox, Andrea M Metzig, Brandon J Coombes, Angela K Fitch, Eric M Bomberg, M Jennifer Abuzzahab

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JAMA pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01237197 (Exenatide in Extreme Pediatric Obesity), which is not on this map. Cited by 81 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 12 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01237197 phase2completednot on this map

Exenatide in Extreme Pediatric Obesity

TypeinterventionalSponsorUniversity of MinnesotaRan2010 to 2012Enrolled26ConditionsObesityArmsExenatide, Placebo
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 12 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.International journal of molecular sciences · 2025
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2017 · on this map
    Guideline
  12. Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016
    Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Aaron S KellyDepartment of Pediatrics, University of Minnesota Medical School, 420 Delaware St, SE, MMC 715, Minneapolis, MN 55455, USA. kelly105@umn.edu
Kyle D Rudser
Brandon M Nathan
Claudia K Fox
Andrea M Metzig
Brandon J Coombes
Angela K Fitch
Eric M Bomberg
M Jennifer Abuzzahab
University of Minnesota · USDiabetes Australia · AUTwin Cities Orthopedics · USUniversity of Minnesota Medical Center · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
UNIVERSITY OF MINNESOTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UMN CTSI)UL1RR033183 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$8.9M
NCATS NIH HHS 8UL1TR000114-02NCATS NIH HHS UL1 TR000114NCRR NIH HHS 1UL1RR033183NCRR NIH HHS UL1 RR033183
6 · The paper itself

Abstract

importanceMedical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity.

objectiveTo evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity.

designThree-month, randomized, double-blind, placebo-controlled, multicenter clinical trial followed by a 3-month open-label extension.

settingAn academic medical center and an outpatient pediatric endocrinology clinic. PATIENTS: A total of 26 adolescents (12-19 years of age) with severe obesity (BMI ≥ 1.2 times the 95th percentile or BMI ≥ 35).

interventionAll patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day.

main outcome measuresThe primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months.

resultsTwenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (-2.70% [95% CI, -5.02% to -0.37%]; P = .03). Similar findings were observed for absolute change in BMI (-1.13 [95% CI, -2.03 to -0.24]; P = .02) and body weight (-3.26 kg [95% CI, -5.87 to -0.66 kg]; P = .02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the open-label extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%). CONCLUSIONS AND RELEVANCE: These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.

trial registrationclinicaltrials.gov Identifier: NCT01237197.

Indexed as

Body Mass IndexAdolescentBody ConstitutionDouble-Blind MethodExenatideFemaleGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsMalePeptidesReceptors, GlucagonSatiety ResponseVenomsExenatideGLP1R protein, humanGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHypoglycemic AgentsPeptidesReceptors, GlucagonVenoms

Identifiers

PMID23380890
PMCPMC4010226
OpenAlexW2014250290

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.